Nurix Therapeutics Inc
Company Profile
Business description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Contact
1700 Owens Street
Suite 205
San FranciscoCA94158
USAT: +1 415 660-5320
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 November 2025
Employees
286
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,743.60 | 30.00 | -0.34% |
| CAC 40 | 7,691.55 | 134.24 | 1.78% |
| DAX 40 | 24,033.22 | 383.92 | 1.62% |
| Dow JONES (US) | 43,819.27 | 432.43 | 1.00% |
| FTSE 100 | 8,798.91 | 63.31 | 0.72% |
| HKSE | 24,284.15 | 41.25 | -0.17% |
| NASDAQ | 20,273.46 | 105.55 | 0.52% |
| Nikkei 225 | 40,150.79 | 566.21 | 1.43% |
| NZX 50 Index | 12,583.59 | 103.54 | 0.83% |
| S&P 500 | 6,173.07 | 32.05 | 0.52% |
| S&P/ASX 200 | 8,514.20 | 36.60 | -0.43% |
| SSE Composite Index | 3,424.23 | 24.23 | -0.70% |